Daniel is Founder and Chief Executive Officer and board member at ProQR Therapeutics (NASDAQ: $PRQR), a biopharma company dedicated to developing RNA Editing medicines for genetic diseases. Mr. de Boer is a serial entrepreneur and passionate advocate for rare disease patients. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding ProQR, Mr. de Boer was founder and Chief Executive Officer of several technology companies. He is also strategic advisor at Hybridize Therapeutics, Meatable, Algramo, Xinvento, Avanzanite, BioColl Labs, a member of the advisory board at the Termeer Foundation, board member at Fair Therapeutics and board member at the Ain Foundation. In 2018 Mr. de Boer was named "Emerging Entrepreneur of the Year" by EY. In 2019 Mr. de Boer was selected for the Young Global Leader program at the World Economic Forum.